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Abstract
Background: Local and volatile anesthetics are widely used for surgery. It is not known whether anesthetics impinge on the
orchestrated events in spontaneous resolution of acute inflammation. Here we investigated whether a commonly used local
anesthetic (lidocaine) and a widely used inhaled anesthetic (isoflurane) impact the active process of resolution of
inflammation.
Methods and Findings: Using murine peritonitis induced by zymosan and a systems approach, we report that lidocaine
delayed and blocked key events in resolution of inflammation. Lidocaine inhibited both PMN apoptosis and macrophage
uptake of apoptotic PMN, events that contributed to impaired PMN removal from exudates and thereby delayed the onset
of resolution of acute inflammation and return to homeostasis. Lidocaine did not alter the levels of specific lipid mediators,
including pro-inflammatory leukotriene B4, prostaglandin E2 and anti-inflammatory lipoxin A4, in the cell-free peritoneal
lavages. Addition of a lipoxin A4 stable analog, partially rescued lidocaine-delayed resolution of inflammation. To identify
protein components underlying lidocaine’s actions in resolution, systematic proteomics was carried out using nanospray-
liquid chromatography-tandem mass spectrometry. Lidocaine selectively up-regulated pro-inflammatory proteins including
S100A8/9 and CRAMP/LL-37, and down-regulated anti-inflammatory and some pro-resolution peptides and proteins
including IL-4, IL-13, TGF-a ˆ and Galectin-1. In contrast, the volatile anesthetic isoflurane promoted resolution in this system,
diminishing the amplitude of PMN infiltration and shortening the resolution interval (Ri) ,50%. In addition, isoflurane
down-regulated a panel of pro-inflammatory chemokines and cytokines, as well as proteins known to be active in cell
migration and chemotaxis (i.e., CRAMP and cofilin-1). The distinct impact of lidocaine and isoflurane on selective molecules
may underlie their opposite actions in resolution of inflammation, namely lidocaine delayed the onset of resoluion (Tmax),
while isoflurane shortened resolution interval (Ri).
Conclusions: Taken together, both local and volatile anesthetics impact endogenous resolution program(s), altering specific
resolution indices and selective cellular/molecular components in inflammation-resolution. Isoflurane enhances whereas
lidocaine impairs timely resolution of acute inflammation.
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Introduction
Resolution of acute inflammation was widely held to be a passive
event [1]. It is now clear that tissue resolution or its return from an
inflammatory and/or disease state is an active process involving
novel mediators [2,3]. Non-resolved inflammation can exacerbate
tissue injury and may cause functional damage via abscess or scar
formation [1]. An emerging body of evidence now indicates that
anti-inflammation (i.e. inhibiting the cardinal signs of inflammation
[1]) and pro-resolution, namely activating endogenous resolution
programs [3] are distinct mechanisms in the control of inflamma-
tion [3,and for a recent consensus report, see ref 4]. Classic
antiinflammatories are enzyme inhibitors and/or receptor antago-
nists such as inhibitors of cyclooxygenases (COX) and antagonists
for leukotriene (LT) receptors. Resolution agonists, in comparison,
are also antiinflammatories, but act by different mechanisms than
the classic ones [recently reviewed in ref 5].
Resolution agonists (such as lipoxins), for example, are agonists
that not only block neutrophil (PMN) actions [5], but also
stimulate non-phlogistic monocyte recruitment [6] and macro-
phage uptake of apoptotic PMN [7]. Hence resolution agonists
have two main mechanisms of actions at the tissue level; they lower
the numbers of infiltrating PMN to the inflamed sites and tissues;
and they stimulate the active removal of debris and apoptotic
PMN from the inflamed sites by non-phlogistic activation of
macrophages [5]. Because it is important to study resolution of
inflammation as a distinct process, we introduced resolution
indices to a) quantitate the overall process; b) access the roles of
specific mediators; and c) pinpoint mechanisms of pharmacolog-
ical interventions in the resolution of inflammation.
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1879To characterize resolution of inflammation in cellular and
molecular terms, we established a resolution map and defined the
main quantitative indices (Fig. S1A) [8]. These indices chart and
take into account (i) the magnitude of PMN tissue infiltration
(maximal PMN, Ymax); (ii) the time interval when numbers of
PMN reach Ymax within exudates (Tmax); (iii) duration: the time
point (T50) when PMN numbers reduce to 50% of Ymax (R50); and
(iv) the resolution interval (Ri): the time interval from the maximum
PMN point (Ymax) to the 50% reduction point (R50)[ i.e.
T50-Tmax]. Using this set of resolution indices, we demonstrated
that endogenous mediators such as resolvins and protectins
accelerate resolution as evidenced by initiating the resolution of
inflammation at earlier times (QTmax and T50) and/or shortening
the resolution interval (QRi) [8,9]. The actions of these pro-
resolution mediators sharply contrast those of agents and currently
used therapeutics that are inhibitors and ‘‘resolution toxic’’. These
drugs/agents have an unwanted impact on resolution such as
inhibitors of COX-2 [9,10] and lipoxygenases (LOX) [9]. Thus,
this set of resolution indices can be utilized to evaluate the impact
of endogenous mediators as well as potential new therapeutic
agents in inflammatory resolution because they reflect the
summation of tissue-level events that are multi-level cellular and
molecular processes in resolution of inflammation.
Surgery itself initiates an inflammatory response [11], and local
anesthetics, both topical and volatile, are widely used during
surgery [12]. Some anesthetics (i.e., lidocaine and isoflurane) are
reported to reduce inflammatory markers, including cytokines and
chemokines [13,14]. Potential impact of these widely used
anesthetics on resolution of inflammation has not been established.
The actions of many widely used current drugs in the
pharmacopeia on resolution of inflammation remain unknown
because their resolution characteristics were not evaluated at the
time of their classical development. Appropriate qualified models
of resolution were simply not yet available [8,9].
Here, we report using an unbiased systems approach that the
widely used local anesthetic, lidocaine, and a widely used volatile
anesthetic, isoflurane, each impact in vivo the resolution of acute
inflammation in opposite directions that were quantified using
resolution indices. We also characterize their multi-level impact on
key cellular and molecular components in resolution of inflam-
mation.
Results
Local anesthetic lidocaine impairs resolution
We first determined whether lidocaine alters cellular infiltration
in a self-limited spontaneously resolving murine peritonitis. For
these analyses, we used our reported resolution map that was
constructed using an unbiased systems approach that combined cell
trafficking into inflammatory exudates and mass spectrometry-
based proteomics and lipid mediator lipidomics of resolving
exudates [8]. Here, a microbial stimulus, the yeast wall zymosan
A, was administered intraperitoneally to initiate inflammation [15],
together with lidocaine given concomitantly. Given the inflamma-
tion-resolution map as a background terrain, lidocaine was
introduced in order to determine if it significantly changed the
signature of resolution map and indices in zymosan-initiated
peritonitis. Inflammatory exudates were collected at the indicated
time intervals 4–72 h (Fig. 1A). Zymosan alone, as expected,
stimulated an acute increase in the total leukocyte numbers (i.e.
PMN and mononuclear cells) present in the peritoneal exudates
during the initial phase of inflammation (4 h after zymosan,
11.860.4610
6 leukocytes), with a maximal infiltration at 12 h
(30.062.5610
6 leukocytes), followed by a decline or resolution as
monitored to 72 h. The time course of PMN infiltration followed a
similar trend, peaking (17.562.5610
6 PMN) at 12 h after zymosan
challenge (Fig. 1A). An anesthetic dose of lidocaine, i.e. 0.08% (w/v)
[16] administered with zymosan A significantly increased the
number of total leukocytes by ,49% within exudates at 4 h
(p,0.05).Theincrease inexudate PMNwas,58%(p,0.05).Inthe
mice treated with both lidocaine and zymosan, the numbers of
PMN continued to increase after 12 h and reached a maximum at
24 h. As a result, in the presence of lidocaine, the number of PMN
in the exudate was significantly increased at this time point (,60%
increase, p,0.01). In contrast, the patterns of mononuclear cell
infiltrates did not appear to be significantly altered by lidocaine
treatment in this time course (4–72 h). Even doses as low as 0.008%
(w/v) lidocaine, when given together with zymosan, led to a
significant increase in the accumulation of PMN at 24 h (,75%
increase, p,0.001). Lidocaine alone without zymosan challenge did
not alter peritoneal leukocyte numbers in this 4–24 h interval after
administration (Fig. S1B). These results suggested that lidocaine
might hamper PMN clearance during the normal spontaneous
resolution phase of acute inflammation.
As shown in Figures 1A and S1C, in the zymosan-initiated
peritonitis, the number of PMN reached a maximum at 12 h. The
time intervals between 12 h (Tmax) and 35 h (T50), exudate PMN
decreased in number from 17.5610
6 PMN (Ymax; maximal PMN
number) to 8.8610
6 PMN (R50; essentially 50% reduction of
PMN). This period of neutrophilic loss from the exudates is termed
the resolution interval (Ri) [8]. In mice treated with zymosan alone, Ri
was ,23 h (i.e., 12–35 h). When the resolution indices were
calculated with lidocaine treatment together with zymosan, it was
apparent that both the anesthetic (0.08%) and sub-anesthetic doses
(0.008%) of lidocaine increased Ymax and shifted the onset of Ri
from 12 h to a later time point (Tmax=24 h) (see Fig. S1C and vide
infra). These results demonstrate that lidocaine directly delayed the
spontaneous resolution of zymosan-initiated acute inflammation.
Especially, lidocaine increased the dwell time of PMN present
within the exudates, possibly blocking the clearance of PMN from
the exudates in vivo (see below).
Surgery can induce local inflammation via tissue injury, and
lidocaine is usually given before surgery [11,12]. In order to mimic
such a clinical scenario, mice were treated with lidocaine (0.08%)
15 min before initiation of acute inflammation by zymosan. This
prior exposure to lidocaine significantly potentiated zymosan-
initiated leukocyte infiltration at 24 h by ,40% (cf. zymosan
alone, p,0.01). This is similar to the results obtained with mice
that received lidocaine and zymosan together, which gave a
,33% increase in the number of leukocytes present in the
exudates when compared to zymosan alone (p,0.05, Fig. 1B).
Thus, lidocaine administration, either just before or concomitant
with zymosan, caused significant increases in the number of PMN
present in exudates in the resolution phase of acute inflammation.
Specialized lipid mediators play a key role in resolution of
inflammation [5] with some specifically switched on during the
resolution phase to promote resolution [17]. Here, key lipid
mediators were monitored in murine exudates, including lipoxin
(LX) A4, an anti-inflammatory and pro-resolution mediator, and
the pro-inflammatory LTB4 and prostaglandin (PG) E2. In this
system, the maximal levels present in cell-free lavages of the
exudates of both LTB4 and LXA4 were obtained at 4 h. These
subsequently subsided within 24 h (Fig. 2A). Lidocaine did not
significantly alter the levels of LXA4, LTB4 or PGE2 present in
these cell-free lavages of the peritoneal exudates. Thus, these
eicosanoids likely reflect the profile from resident peritoneal cells
including macrophages as are less likely to report eicosanoids
generated by the infiltrating leukocytes.
Anesthetics Impact Resolution
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regulating leukocyte infiltration, stimulating macrophage clear-
ance of apoptotic PMN and also their exit via lymphatics [5,8,9].
Since LXA4 can rescue inhibitor-imposed lesion with, for example,
a selective COX-2 inhibitor [9], we questioned whether these
resolution agonists impact leukocyte infiltration in lidocaine-
treated mice. At 24 h, lidocaine (0.08%, ,0.8 mg) administration
increased, while ATLa (a stable analog for aspirin-triggered 15-
epi-lipoxin A4, 300 ng, i.p.) decreased exudates cell numbers,
when compared with mice treated with zymosan alone. When
ATLa was administered along with lidocaine and zymosan, it
significantly reduced exudate leukocytes compared to mice
received lidocaine and zymosan (p=0.04) (Fig. 2B). Thus, pro-
resolution mediators, such as lipoxins, at much lower doses (by
more than 3 log orders) partially rescued the defective resolution of
inflammation caused by lidocaine.
Lidocaine impairs PMN apoptosis and their removal by
macrophages
PMN apoptosis and their subsequent removal by macrophages
are essential components of resolution at the tissue level [1,18].
Since lidocaine delayed PMN clearance in the resolution phase,
we considered that lidocaine might have an impact on PMN
apoptosis. To address this, peritoneal cells were collected at 24 h
after zymosan challenge, well within the resolution phase, and
labeled with FITC-annexin-V and PE-conjugated anti-Gr-1 Ab, a
specific cell surface marker for mouse PMN. Peritoneal cells
collected from mice receiving lidocaine (at both 0.08% and
0.008%) together with zymosan showed significantly decreased
annexin-V
+Gr-1
+ cells by 50% and 64%, respectively, indicating
reduced PMN apoptosis (Fig. 3A). At 48 h after zymosan
challenge, lidocaine at 0.08% also reduced PMN apoptosis
,40% (p,0.01).
We next determined whether lidocaine impacts macrophage
ingestion of PMNs. To this end, we carried out a phagocytosis-
based analysis in vivo (Fig. 3B). Exudate cells were collected at 24 h
after zymosan challenge, and macrophages were labeled with the
FITC-conjugated anti-F4/80 Ab. This was followed by permea-
bilization of these cells, allowing labeling of ingested PMN with
PE-conjugated anti-Gr-1 Ab. Cells with positive staining of both
F4/80 and Gr-1 were then monitored by FACS analysis. Of
interest, cells collected from mice treated with lidocaine (0.08%)
together with zymosan showed significantly reduced F4/80
+Gr-1
+
cells (18.061.2%) when compared to those given only zymosan
(28.461.6%) (p,0.05, Fig. 3B). The low dose of lidocaine
(0.008%) also gave decreased F4/80
+Gr-1
+ cells (24.862.1%),
albeit not significantly different from mice receiving zymosan
alone. These results indicate that clinically used doses of lidocaine
inhibit macrophage ingestion of apoptotic PMN in vivo, blocking
their removal and resolution.
We also investigated whether lidocaine has a direct impact on
isolated macrophages. To this end, we carried out in vitro
phagocytosis of zymosan particles. This system represents
Figure 1. Lidocaine alters leukocyte infiltration during acute
inflammation and delays resolution. (A) Mice were injected with
zymosan A in the absence or presence of lidocaine (0.008% or 0.08%)
and peritoneal lavages were collected at indicated time points. Total
leukocytes were enumerated by light microscopy, and PMN and
mononuclear cells determined by differential leukocyte counting.
Results are expressed as the mean6SEM from n=3–4. *p,0.05,
**p,0.01, ***p,0.001 when compared to mice treated with zymosan
A alone at the same time points. (B) Mice were injected with lidocaine
(0.08%) 15 min prior to injection of zymosan A. Peritoneal lavages were
collected at 24 h, and total leukocytes enumerated. Results are
expressed as mean6SEM from n=3. *p,0.05, **p,0.01 when
compared to mice treated with zymosan A alone.
doi:10.1371/journal.pone.0001879.g001
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Recently, we found that pro-resolution mediators such as LXA4
are potent stimulators of macrophage uptake of microbial
particles, i.e., opsonized zymosan [9], in addition to stimulating
the uptake of apoptotic PMN [7]. Of interest, lidocaine at both
doses (0.008% and 0.08%), when added together with LXA4,
significantly impaired LXA4-stimulated phagocytosis (Fig. 3C).
Thus, lidocaine can be considered ‘‘resolution toxic’’ because it
impairs key components at the level of tissue resolution, namely
PMN apoptosis and macrophage phagocytosis, and blocks the
protective action of LXA4.
Lidocaine regulates both anti- and pro-inflammatory
proteins: proteomics
Using mass spectrometry-based resolution proteomics, we
recently identified several components in inflammatory exudates,
including haptoglobin, S100A9 and a1-macroglobulin, that may
play active roles in promoting resolution of inflammation [8].
These proteins were identified by peptide mapping of in-gel
digested proteins using capillary liquid chromatography-nanos-
pray ion trap tandem mass spectrometry (nanospray-LC-MS-MS)
and bioinformatics software (see Methods). Among these, S100A9
was present in exudates within 4 h of initiating inflammation and
reached maximum levels at the onset of Ri (12 h). These changes
in S100A9 paralleled the time course of PMN infiltration (Fig. 1A)
[8]. Both S100A8 and S100A9 are known to be abundant cytosolic
proteins in human PMN that can be secreted and exhibit potent
actions in inflammatory cell recruitment [20]. Also, S100 proteins
belong to a new group of damage-associated molecular pattern
proteins and may function as "alarm/danger" signals to propagate
inflammation [21]. To determine whether lidocaine impacts these
proteins during inflammation-resolution, we carried out temporal-
differential analysis of peritoneal exudate proteins collected from
zymosan-challenged mice in the presence or absence of the
anesthetic dose of lidocaine (0.08%). Two time intervals were
selected for analysis: one at 4 h within the early inflammatory
phase, and the second at 24 h within the resolution phase, since
lidocaine gave the most dramatic impact on PMN infiltration at
these two time points (see Fig. 1A). Four hours after zymosan
challenge, both S100A8 and S100A9 were significantly increased
in the presence of lidocaine (Fig. 4A and Table 1). This increase
was verified from mice that received lidocaine together with
zymosan by Western blot analysis that also demonstrated an
increase in S100A9 proteins in exudates (Fig. 4B). Also S100A9
mRNA levels were higher in these mice compared to mice that
received zymosan alone as determined with RT-PCR (Fig. 4B).
Thus, it is likely that S100A8/A9 complexes reflect, at least in
part, the increases in PMN obtained in mice challenged with
lidocaine and zymosan at 4 hours, compared to mice received
zymosan alone.
We also determined, in parallel with exudate cells, changes in
cell-associated proteins from these mice. As shown in Figure 4C,
lidocaine together with zymosan at 4 h gave significant up-
Figure 2. Lidocaine did not directly alter selective eicosanoid
levels in cell-free exudates: LXA4 rescues lidocaine-delayed
resolution. (A) Cell-free lavages from murine peritoneum were
collected at indicated time points after zymosan challenge (1 mg/ml).
LXA4, LTB4 and PGE2 amounts were determined by ELISA. Results are
expressed as the mean6SEM from duplicates of n=3, and were
expressed as amounts (ng/ml). (B) Mice were injected with zymosan A
together with lidocaine (0.08%), ATLa (300 ng), or lidocaine plus ATLa.
Peritoneal lavages were collected at 24 h, and total leukocytes
enumerated. Results are expressed as mean6SEM from n=3.
*p=0.03 **p=0.01 when compared to mice treated with zymosan A
alone. ***p=0.04 when compared to mice treated with zymosan A and
lidocaine.
doi:10.1371/journal.pone.0001879.g002
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1879Figure 3. Lidocaine impairs PMN apoptosis and macrophage ingestion of PMN in vivo and zymosan in vitro. (A) Apoptosis in vivo.
Peritoneal cells were collected at 24 h or 48 h and labeled with FITC-annexin-V and PE-conjugated anti-Gr-1 Ab. The apoptotic PMN (annexin-V
+Gr-1
+)
are expressed as % of total PMN (Gr-1
+). Results are the mean6SEM from n=3–4. *p,0.01, **p,0.001. (B) Phagocytosis in vivo.( right) Representative
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challenged mice. Among them, CRAMP (cathelin-related anti-
microbial peptide), the mouse homolog of anti-microbial protein
LL-37, was increased approximately two-fold (Table 1). CRAMP
is also a documented chemotactic factor for PMN, monocytes,
mast cells, and T cells [22]. Thus, exudate CRAMP/LL-37 may
also contribute to increased PMN numbers obtained at 4 h in
lidocaine-treated mice (Fig. 1A). Moreover, we found that, within
resolution at 24 h, lidocaine down-regulated galectin-1 ,50%
(Fig. 4C and Table 1). Galectin-1 inhibits PMN migration during
PMN-endothelial interactions in vitro and in vivo [23]. In
addition, Galectin-1 prolongs exposure of phosphatidylserine on
the surface of leukocytes, suggesting a role in promoting PMN
clearance [24]. Therefore, decreases in Galectin-1 levels from
lidocaine-treated mice during resolution (i.e. 24 h) might also
contribute to delayed PMN clearance, resulting in increased PMN
dwell times in exudates (Fig. 1A).
Lidocaine impacts chemical mediators in exudates
Production of both pro-inflammatory (e.g. IL-1b, IL-6, IL-12,
TNF-a) and anti-inflammatory (e.g. IL-4, IL-10, and IL-13)
cytokines is essential in the control of inflammation [25]. Here, we
monitored a panel of chemokines and cytokines in exudates to
assess whether lidocaine specifically regulates their levels. At 4 h
after zymosan challenge, most cytokines and chemokines were
dramatically up-regulated compared to naı ¨ve mice (Fig. 5A). Of
interest, both 0.08% and 0.008% lidocaine gave similar results at
4 h, with significant, preferential reduction of anti-inflammatory
cytokines, including IL-4, IL-10 and IL-13 (Fig. 5B). In addition,
anesthetic dose of lidocaine decreased pro-inflammatory KC (the
murine homolog of human IL-8) without significant changes in
other pro-inflammatory cytokines and chemokines in the exudates,
suggesting that lidocaine acts at several levels in acute inflamma-
tion, overall reducing what is coined the ‘‘cytokine/chemokine
storm’’ observed in the early inflammatory response (4 h) (Fig. 5A).
In murine peritoneal exudates, lidocaine initially reduced the
levels of most of the chemokines and cytokines induced by
zymosan at 4 h, but increased their levels by 12 h (Table 2).
Calculation of the ratios between pro- and anti-inflammatory
cytokines (TNF-a/IL-10 or IL-6/IL-10) indicated that lidocaine
increased these ratios in the resolution phase (12 and 24 h after
zymosan A injection) (Table 3). These changes in ratios (i.e. pro-/
anti-inflammatory cytokines) likely contribute to the increased
numbers of PMN present in the resolution phase (i.e. 12-24 h),
compared to the mice not treated with lidocaine. We also found
that lidocaine (0.08%) significantly decreased exudate levels of
TGF-b at the late resolution phase, 48 h after zymosan challenge
(Fig. 5C). It is likely that the decreased levels of TGF-b contributed
to impaired macrophage phagocytosis in lidocaine-treated mice
(Fig. 3B), that can lead to delayed PMN clearance and their
increased dwell time. The impact of lidocaine was also evaluated
in human whole blood ex vivo to access whether the murine system
reflects human tissue events. The anesthetic dose of lidocaine
(0.08%) significantly diminished the levels of a panel of
chemokines and cytokines in zymosan-stimulated human whole
blood (Fig. 5D).
Volatile anesthetic isoflurane promotes resolution
Isoflurane 1.4 MAC (minimum alveolar concentration) was
administrated over a 2 h period (from 1 h before to 1 h after
zymosan challenge) to mimic clinical use. Exudates were collected
during inflammation-resolution to determine the potential impact
of isoflurane in the resolution maps and indices. Isoflurane
significantly reduced zymosan-stimulated leukocyte infiltration at
12, 24 and 48 h (Fig. 6A). When compared to mice that received
zymosan alone, at the peak of inflammation, Tmax, isoflurane
decreased maximal PMN numbers (Ymax) from 18.0610
6 to
13.5610
6. In addition, isoflurane dramatically reduced T50 from
,34 h to ,22 h, thus shortening Ri by .50% from ,22 h to
,10 h (Fig. 6B). These results contrast with lidocaine’s impact on
the resolution indices where lidocaine delayed the onset of
resolution, i.e. Tmax (Table 4).
Isoflurane specifically regulates key exudate proteins
Since isoflurane gave the most dramatic reduction on zymosan–
stimulated PMN infiltration at two time intervals (Fig. 6A), these
intervals were selected for exudate proteomic analysis: First, the
early resolution phase at 12 h, and second, the late resolution
phase at 24 h after zymosan challenge (Fig. 7A). At 12 h after
zymosan challenge, we found CRAMP, an anti-microbial protein
and chemotactic factor was decreased ,2-fold (Table 5) in mice
that received 1.4 MAC isoflurane, contrasting with significant
increase of CRAMP at 24 h mediated by lidocaine (Table 1). In
addition, isoflurane reduced cofilin-1 (Table 5), a major actin-
depolymerization factor regulating actin dynamics and generation
and maintenance of cell protrusions, key cellular events that are
required for migration [26]. Therefore, during resolution of
inflammation, isoflurane selectively regulates cellular proteins that
are involved in cell migration and chemotaxis (i.e., CRAMP and
cofilin-1). By comparison, isoflurane treatment increased SH3
domain-binding glutamic acid-rich like protein (SH3BGRL),
which might have anti-oxidative and anti-inflammatory properties
[27,28].
We monitored in the exudates a panel of chemokines and
cytokines to examine whether isoflurane regulates their levels in
vivo. Of interest, isoflurane-treated mice selectively reduced
zymosan-stimulated pro-inflammatory cytokine levels (IL-1b, IL-
6, IL-12, KC, JE [the mouse homolog of human MCP-1], MIP-1a
and Rantes) (Fig. 7B, Tables 6 and 7), but did not apparently affect
the levels of cytokines IL-4, IL-10 and IL-13 in the early
inflammatory phase, 4 h after zymosan challenge (Fig. 7B).
Discussion
A systems approach to mapping the resolution of acute
inflammation demonstrated that resolution is an active process
[2,3] and a new terrain of cellular and molecular processes
directed toward returning the tissue to homeostasis [8,29]. Using
this differential-temporal and quantitative systems approach to
analyze inflammation and its spontaneous resolution, we identi-
fied, for the first time, in the present report that widely used
anesthetics impact the resolution of acute inflammation. Lido-
caine, the first amino amide-type local anesthetic is well
dot plots of FACS analysis. In the non-permeabilized lavage cells, Gr-1
+ represents PMN, and F4/80
+ represents macrophages; and in the
permeabilized cells, F4/80
+Gr-1
+ cell population represents macrophages with ingested PMN. (left) Results are expressed as the mean6SEM from
n=3–4, and were expressed as percent of the F4/80
+Gr-1
+ cells. *p,0.05. (C) Phagocytosis in vitro. Murine peritoneal resident macrophages were
incubated with indicated compounds or vehicle alone for 20 min followed by addition of FITC-zymosan at a 10:1 ratio for 30 min. Cells were then
quenched and fluorescence determined. Phagocytosis activity in the presence of 1 nM of LXA4 was taken as 100%. Results are expressed as the
mean6SEM from n=3–4, and were expressed as % phagocytosis. *p,0.05, **p,0.01, compared to LXA4 alone.
doi:10.1371/journal.pone.0001879.g003
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voltage gated sodium channels on cell membranes [30]. Earlier
evidence from in vitro studies indicates that lidocaine influences
the immune system by reducing responses such as chemotaxis,
microtubule assembly, phagocytosis, release of lysosomal enzymes
and superoxide anion generation [31–33]. In certain settings,
lidocaine can reduce inflammatory responses and protect tissues
from local injury [34]. On the other hand, lidocaine worsens renal
injury following ischemia-reperfusion by increasing necrosis and
local inflammation [35]. In burn wounds, lidocaine increases
leukocyte numbers, which suggests an increase in PMN infiltration
and/or increased viability of the leukocytes at the burn site [36].
Yet the clinical significance of these observations remains to be
established. The results of the present studies demonstrate that
lidocaine imposes a molecular lesion in resolution that delays the
return to homeostasis. Specifically, lidocaine increases leukocyte
accumulation in exudates, impairs the apoptosis of PMN and
hampers ingestion of apoptotic PMN by macrophages in vivo.
Summation of these multi-level actions in tissues significantly
delays resolution of inflammation.
In this context, other currently and widely used therapeutic
agents also affect resolution of inflammation. Aspirin, for example,
by way of initiating biosynthesis of endogenous lipid mediators
(i.e., aspirin-triggered epimer of lipoxin A4 [ATL] and resolvin
E1), promotes resolution [4,9]. Cyclin-dependent kinase and
specific ERK1/2 inhibitors, in comparison, also promote resolu-
tion of inflammation by enhancing PMN apoptosis [37,38]. In
contrast, COX or LOX inhibitors, by blocking the biosynthesis of
key lipid mediators, dramatically impairs resolution [9,10]. In the
peritoneal cell-free lavages, LXA4 appeared in the early
inflammatory phase, 4 h after zymosan challenge. PGE2, a signal
that can activate the full LXA4-biosynthetic capacity in vivo [17],
was present in the peritoneum prior to peritonitis and elevated
during the acute inflammatory response. Lidocaine did not alter
either the magnitude or time course of LXA4 in a statistically
significant fashion compared to the mice given zymosan alone.
However, a trend towards reduction was observed at 4, 12 and
48 h. Of interest, when exogenous ATLa (a stable analog of LXA4
and ATL) was given together with lidocaine, it significantly
reversed in part lidocaine’s delaying effects in the resolution of
inflammation. Thus, pro-resolution mediators may have thera-
peutic potential in settings where sustained inflammation and
impaired resolution are components of disease pathophysiology.
Increases in the ratios of IL-6/IL-10 are thought to signify pro-
versus anti-inflammatory response. This increase in ratio corre-
lates with the severity of systemic inflammatory response syndrome
and injury after trauma [39]. Since results from several studies
indicate that the relationship between pro- and anti-inflammatory
cytokines influences the severity of sepsis [40], and TNFa/IL-10
ratios are used as an indicator for disease severity [41], we
calculated the ratios of pro- to anti-inflammatory cytokines
(Table 3) and found that lidocaine increased these values in the
late phase (12 and 24 h after zymosan). Thus, changes in the
balance between pro- and anti-inflammatory cytokines, rather
than individual chemokines or specific cytokines, appear to
contribute to the observed increases in PMN numbers obtained
at 24 h with lidocaine.
It is noteworthy that, during an inflammatory disease state, a
complex network of interactions between different cytokines is
likely to occur. The timing of cytokine release and the balance
between pro- and anti-inflammatory cytokines is likely to
contribute to the overall outcome and severity, as both pro- and
Figure 4. Lidocaine alters pro- and anti-inflammatory proteins: proteomics and cellular proteins. Mice were injected with zymosan A in
the absence or presence of lidocaine. Both lavage fluids (A) and cell pellets (C) were collected at indicated time points and proteins separated by two-
dimensional gel electrophoresis. Changes in individual protein levels were measured by image analysis. Selected proteins that display significant
differences between treatments are indicated by arrows, and identified by LC/MS/MS and peptide mapping (see Materials and Methods). (B) (Left)
S100 A9 protein levels. Supernatants from peritoneal lavages were subjected to Western blot analysis using an anti-S100A9 antibody. Relative
intensities of immunoreactive bands were quantitated and normalized by albumin levels using an anti-albumin antibody. Data are expressed as
mean6SEM from n=3–4. *p=0.02. (Right) S100 A9 mRNA levels. Peritoneal cells were collected and total RNA isolated for RT-PCR analysis using
specific primers for mouse S100A9. Relative intensities of RT-PCR products were quantitated and normalized by b-actin message levels. Data are
expressed as mean6SEM from n=3–4. *p,0.01.
doi:10.1371/journal.pone.0001879.g004
Table 1. Exudate and cellular proteins regulated by lidocaine during inflammation-resolution
Spot Protein Time (h)
# identified
peptides Zymosan A Zymosan A+Lidocaine P value
Exudate protein
a S100A8 4 2 0.1860.07 0.3960.08 (q117%) 0.02
b S100A8 4 2 0.1160.02 0.4260.10 (q282%) 0.01
c S100A9 4 2 0.0760.05 0.2360.06 (q229%) 0.02
d Apolipoprotein CIII 24 2 0.3260.03 0.2260.02 (Q31%) 0.01
e Fibrinogen c polypeptide 24 8 2.3260.04 1.8760.17 (Q20%) 0.01
f Fibrinogen b polypeptide 24 16 3.9760.36 2.5960.36(Q35%) 0.01
Cellular protein
g CRAMP (LL-37) 4 2 0.2760.08 0.4160.04 (q52%) 0.05
h CRAMP (LL-37) 4 3 0.1460.06 0.2960.05 (q107%) 0.03
i Galectin 1 24 2 0.4960.06 0.2360.08 (Q53%) 0.01
The proteins were identified by mass spectrometry (see Materials and Methods).
doi:10.1371/journal.pone.0001879.t001
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PLoS ONE | www.plosone.org 9 April 2008 | Volume 3 | Issue 4 | e1879anti-inflammatory mediators interact in highly specific ways.
Along these lines, computational simulations were carried out to
address these complex interactions in the setting of acute
inflammation as well as simulate certain disease scenarios and
the time course of cytokine levels in mice [42]. This approach may
lead to in silico development of new therapeutics and real-time
diagnostics.
The volatile anesthetic isoflurane binds to gamma-aminobutyric
acid type A (GABAA) receptors, glutamate and glycine receptors,
and inhibits conduction in activated potassium channels [30]. It is
noteworthy that human peripheral mononuclear cells express
several GABAA receptor subunits, and application of GABA
reduced formyl peptide (fMLP)-stimulated increases in intracellular
Ca
2+ levels [43]. Thus, these GABA receptors may play a role in
modulating immune responses. Along these lines, isoflurane is
known to impact the inflammatory response, reducing inflamma-
tioninvivo[14], increasingleukocyterolling velocities inmesenteric
microcirculation [44], and decreasing activation of the L-selectin
and b2-integrins CD11a and CD11b involved in these responses
[45]. In the present report, we identified specific proteins in
inflammatory exudates and cytoskeleton protein cofilin-1 that were
reduced by volatile anesthetics and are known to be important in
cell migration. In addition, isoflurane treatment increased
SH3BGRL. The human homolog of SH3BGRL belongs to the
thioredoxin-like protein superfamily [27]. Among them, thiore-
doxin-1 (TRX) is a small multifunctional protein with antioxidative
and redox-regulating functions [27]. Serum TRX levels were
elevated in patients with inflammatory bowel disease. Also, TRX
significantly ameliorated DSS-induced colitis and colonic inflam-
mation of IL-10 deficient mice [28]. Thus, SH3BGRL and other
thioredoxin-like proteins might have anti-inflammatory properties,
and contribute to the accelerated resolution in isoflurane-treated
mice documented in the present report (Fig. 6). Of interest, LXA4
stimulates IL-10 [9] as well as heme oxygenase-1 [46,47] and, as
indicated in the present report, was able to partially rescue the
lidocaine-delayed resolution of inflammation (Fig. 2B).
Isoflurane and lidocaine gave opposite effects in the resolution
of acute inflammation, as indicated by their differential impact in
the resolution indices (Table 4). This reflects their distinct and
selective impact on specific molecules involved in resolution of
inflammation. For example, CRAMP protein levels were de-
creased in mice with isoflurane, contrasting with significant
increases in CRAMP at 24 h as evoked by lidocaine, compared
with mice given zymosan alone. Thus, it is likely that the reported
chemotactic property of CRAMP [22] contributes to the observed
opposing actions of isoflurane and lidocaine on peritoneal
leukocyte infiltration. Also, isoflurane selectively reduced zymo-
san-stimulated pro-inflammatory cytokine levels (Fig. 7B and
Tables 6 and 7), which contrasts the events in mice treated with
zymosan and anesthetic dose of lidocaine (0.08%), that signifi-
cantly reduced anti-inflammatory IL-13 (Fig. 5B). Hence, the
changes in these exudates proteins might reflect the opposing
actions of isoflurane and lidocaine in resolution of inflammation.
Historically, the phagocytic index was defined in the cellular era
and was used to determine the average number of bacteria
ingested by phagocyte at single-cell level [48,49]. By comparison,
the resolution indices presented here expand the appreciation of
the complexity of phagocytes at the tissue level and account for the
summation of multi-level cellular and molecular events during
resolution of inflammation. In conclusion, the results of the recent
study indicate that the local anesthetic lidocaine delays the onset of
resolution. The impact of lidocaine is documented herein at multi-
levels in resolution and reflects (i) increased exudate PMNs, (ii)
impaired PMN apoptosis as well as their uptake by macrophages,
(iii) modulating both pro- and anti-inflammatory proteins,
including cytokines and chemokines. Dysregulation of resolution
programs by lidocaine may have important unwanted conse-
quences in both immune responses and host defense that were
previously unappreciated.
Clinical implications of the present observations might be far-
reaching. Every serious surgical intervention unavoidably results in
Figure 5. Lidocaine regulates selective pro- and anti-inflammatory cytokines/chemokines. (A, B) Mice were injected with zymosan alone
or together with lidocaine (0.008% or 0.08%) for 4 h, and peritoneal cell-free lavage fluids collected. Cytokines and chemokines were expressed as (A)
pg/ml or ng/ml in naı ¨ve mice and mice treated with zymosan alone, (B) percent inhibition of zymosan A-induced cytokine/chemokine levels by
lidocaine. The amounts of cytokines and chemokines levels were determined by multiplexed sandwich ELISA. (C) TGF-b (active form) levels were
determined by ELISA. (D) Human heparinized whole blood was incubated with either 0.008% or 0.08% of lidocaine in the presence of zymosan A
(100 mg/ml) for 4 h, and plasma was collected. The amounts of cytokines and chemokines levels were determined by multiplexed sandwich ELISA.
Results are the mean from duplicate determinations of n=3–4. *p,0.05 when compared to mice treated with zymosan A alone (B, C) or human
whole blood incubated with zymosan A alone (D).
doi:10.1371/journal.pone.0001879.g005
Table 2. Regulation of cytokines/chemokines by lidocaine in
murine exudates
Time 4 h 12 h
Lidocaine 0.008% 0.08% 0.008% 0.08%
Pro-inflammatory cytokines
IL-1b +++ + ––
IL-6 – – – * – – +++ +
IL-12 – – – – – – – – – –
IFN-c ––++ –
TNF-a –––* –– +++ * +
K C –––* –––* +++ +
J E –– –– +++ * ++
MCP5 – – ++ + * ++
MIP-1a –– – + –
RANTES – – ++ Ø
TARC – Ø +++ *–
Anti-inflammatory cytokines
IL-4 – – – * – – – * +++ +++
IL-10 – –* Ø +++ +
IL-13 – – – * – – – * +++ * +
TGF-b ØØØ Ø
Mice were administered 1 mg zymosan by intraperitoneal injection in the
absence or presence of lidocaine. Peritoneal lavages were obtained at 4 h and
leukocytes enumerated. Cell-free fluids were collected and amounts of selected
pro-and anti-inflammatory cytokines and chemokines determined by
multiplexed sandwich ELISA. Results are expressed as ‘‘Ø’’: no change, ‘‘–’’: 0–
20% reduction, ‘‘–– ’’: 20–40% reduction, and ‘‘––– ’’: 40–60% reduction; and
‘‘+’’: 0–20% increase, ‘‘++’’: 20–40% increase, and ‘‘+++’’: 40–60% increase of
selective cytokine in the presence of lidocaine compared to mice injected with
zymosan alone. Results represent mean from n=3–4.
* P#0.05
doi:10.1371/journal.pone.0001879.t002
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complications, particularly infection, are directly related to the
degree and length of inflammatory response and resolution of such
response during the postoperative period; therefore, hypothetical-
ly, accelerating resolution of postoperative inflammation should be
helpful in the management of surgical patients during the
postoperative period. Resolution of inflammation would become
a resolution of many problems surgical patients face daily. The
results of the present study offer new avenues, not only for
continued studies in the cellular and molecular markers in
resolution of inflammation, but also for future translational and
clinical research. Also, combining pro-resolution molecules, such
as LXA4 and ATL, together with lidocaine may be a useful
strategy to rescue resolution of acute inflammation. In sharp
contrast, the volatile anesthetic isoflurane accelerates resolution,
shortening resolution interval. Together, these findings demon-
strate, for the first time, the direct impact of anesthetics in the
resolution of inflammatory challenge and the return of the local
tissue to homeostasis.
Materials and Methods
Murine acute inflammation
For lidocaine treatment, male FVB mice (6-8 weeks; Charles
River, Wilmington, MA) were administered lidocaine (0.08% or
0.008%) intraperitoneally together with 1 mg/ml zymosan A (i.p.)
to evoke peritonitis [8] as in accordance with the Harvard Medical
Area Standing Committee on Animals (protocol no. 02570). ATLa
(a stable analog of aspirin-triggered LXA4) was prepared by total
organic synthesis in the Organic Synthesis Core (P50-DE016191).
For isoflurane treatment, mice were administered 1.4 MAC [50]
of isoflurane for a 2 h period (from 1h before to 1 h after injection
of zymosan, i.p.) (see timeline in Fig. 6). At indicated time points,
mice were euthanized with an overdose of isoflurane, and
Figure 6. Volatile anesthetic isoflurane reduces leukocyte infiltration and promote resolution by shortening resolution interval.
Mice were administered 1.4 MAC of isoflurane one hour prior to and after injection of zymosan A (1mg/ml, i.p.) (see timeline). The peritoneal lavages
were collected at indicated time points. (A) Total leukocytes were enumerated by light microscopy, and PMN and mononuclear cells determined by
differential leukocyte counting. Results are expressed as the mean6SEM from n=3-4. *P,0.05 when compared to mice treated with zymosan A
alone at the same intervals. (B) Resolution Indices were calculated with isoflurane as in Figure S1. Isoflurane treatment reduces the magnitude (Ymax)
of inflammation and accelerates resolution by shortening the resolution interval (Ri.).
doi:10.1371/journal.pone.0001879.g006
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saline. Exudate cells and supernatants were obtained for analyses
described below.
Human whole blood
Venous blood (anticoagulated with 10 U/ml sodium heparin)
was collected from healthy non-smoking volunteers who declared
not to have taken any drugs for at least two weeks before the
experiments. Informed consent was obtained from each volunteer.
The protocol was approved by the Brigham and Women’s
Hospital Institutional Review Board (protocol no. 88-02642,
approved 11/26/07). Heparinized whole blood was then incubat-
ed with either 0.008% or 0.08% of lidocaine in the presence of
zymosan A (100 mg/ml) for 4 h, and plasma was collected by
centrifugation at 2,000 rpm for 15 min. The amounts of cytokines
and chemokines levels were determined by multiplexed sandwich
ELISA (SearchLight Proteome Array custom-designed by Pierce
Boston Technology Center). Following a standard sandwich
ELISA procedure, the entire plate is imaged to capture
chemiluminescent signals generated at each spot within each well
of the array. The SearchLight CCD Imaging and Analysis System
features image analysis software that calculates chemokine/
cytokine concentrations (pg/ml) using pre-determined standard
curves.
Differential leukocyte counts and FACS analysis
Aliquots of exudate cells were prepared for determination of
total and differential leukocyte counts. For determination of
cellular composition (PMN vs. mononuclear cells), cells were
blocked with anti-mouse CD16/32 blocking Ab (0.5 mg/0.5610
6
cells) for 5 min and stained (20 min) with FITC-conjugated anti-
mouse CD14 and PE-conjugated anti-mouse Ly-6G (0.5 mg/
0.5610
6 cells; clones rmC5-3 and RB6-8C5, respectively, from
BD Pharmingen, San Diego, CA). FACS analysis was then carried
out.
Apoptosis and phagocytosis
For determining PMN apoptosis in vivo, exudate cells were
labeled with FITC-conjugated anti-annexin-V Ab (0.5 mg Ab/
0.5610
6 cells, eBioscience) and PE-conjugated anti-mouse Gr-1
(Ly-6G) Ab (0.5 mg Ab/0.5610
6 cells, eBioscience) for 20 min.
The annexin-V
+Gr-1
+ PMN population was determined by
FACS.
For determining macrophage phagocytosis of apoptotic PMN in
vivo, cells were blocked with anti-mouse CD16/32 blocking Ab
(0.5 mg/0.5610
6 cells) for 5 min, stained with FITC-conjugated
Figure 7. Isoflurane regulates cellular proteins-proteomic
analysis. Mice were administered 1.4 Mac of isoflurane one hour prior
to and after injection of zymosan A (1mg/ml, i.p.). (A) The peritoneal
lavage cells were collected at indicated time points and proteins
separated by two-dimensional gel electrophoresis. Changes in individ-
ual protein levels were measured by image analysis. Selected proteins
that display significant differences between treatments are denoted,
and were identified by LC/MS/MS and peptide mapping. (B) Peritoneal
cell-free lavage fluids were collected. Cytokine and chemokine levels
were determined and expressed as percent inhibition of zymosan A-
induced cytokine/chemokine levels by isoflurane. *p,0.05 when
compared to mice treated with zymosan A alone. For raw values (pg/
ml) of these selective cytokines, see Table 6.
doi:10.1371/journal.pone.0001879.g007
Table 3. Ratios of pro- versus anti-inflammatory cytokines
Time 4 h 12 h 24 h
TNF-a/IL-10
Zymosan A alone 0.5 11.0 43.5
+0.008% lidocaine 0.4 12.5 66.7
+0.08% lidocaine 0.4 11.0 ND
IL-6/IL-10
Zymosan A alone 329.2 236.0 134.0
+0.008% lidocaine 232.7 301.0 177.0
+0.08% lidocaine 254.8 251.0 ND
ND, not determined.
doi:10.1371/journal.pone.0001879.t003
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6 cells) for 20 min, and then
permeabilized with 0.1 % Triton X-100 (100 ml, 10 min).
Permeabilized cells were then stained with PE-conjugated anti-
mouse Ly-6G (0.5 mg/0.5610
6 cells). The F4/80
+Gr-1
+ cell
population was determined by FACS.
For phagocytosis in vitro, murine peritoneal resident macro-
phages were collected and plated onto 24-well plates (1610
5cells/
well) and incubated with lidocaine (0.008% or 0.08%), LXA4 (1
nM; Calbiochem) or both for 20 min. FITC-zymosan (2.5 ml/well)
was then added to macrophages for 30 min. Supernatant was
aspirated and extracellular fluorescence was quenched by adding
trypan blue for 1 min. Cells were then washed and intracellular
fluorescence was determined by a fluorescent plate reader.
Two-dimensional gel-based proteomics
Two-dimensional gel electrophoresis. Supernatants and
cell pellets from peritoneal lavages were collected by centrifugation
(15 min, 1,800 rpm) in the presence of protease inhibitors (Roche,
Indianapolis, IN). Proteins in the supernatant were desalted by
acetone precipitation, and the protein pellet was re-dissolved in a
lysis solution containing 8 M urea, 4% w/v CHAPS, 40 mM Tris,
and 65 mM dithiothreitol (DTT). The cell pellets were directly
solubilized in the same lysis solution through sonication at 4uC.
The protein concentrations were measured in duplicate by a
Bradford protein assay kit (Bio-Rad, Hercules, CA) in a 96-well
plate format using bovine serum albumin as the standard.
Supernatant (25 mg) or cellular (50 mg) proteins from each
animal were mixed with 125 mL of rehydration buffer
containing 8M urea, 2% (w/v) CHAPS, 10 mM DTT, and
0.2% carrier ampholytes (pH 3–10), and then loaded onto
nonlinear 7-cm, pH 3-10, IPG strips (Bio-Rad) through passive
in-gel rehydration overnight. After iso-electric focusing for
10,000 V-h, the proteins in the IGP strips were reduced with
dithiothreitol and alkylated with iodoacetamide. The 2
nd
dimension separation was then carried out using 10–14% SDS-
PAGE (covering ,MW10 to 200 kDa). Gels were stained with
ProteomIQ
TM blue dye (Proteome Systems, Woburn, MA), and
scanned with a GS-800 densitometer system (Bio-Rad). Image
analysis was carried out with PDQuest software (version 8.0) (Bio-
Rad). The differentially regulated protein spots were selected
based on the normalized spot volumes.
LC-MS-MS proteomics. The selected protein spots were
excised and in-gel digested with sequencing grade trypsin
(Promega, Madison, WI). Tryptic peptides were loaded onto a
2 mg capacity peptide trap (CapTrap; Michrom Bioresources,
Auburn, CA) in 0.1% formic acid and 0.05% trifluoroacetic acid
and separated by capillary liquid chromatography using a capillary
column (75 mm65c m 63 mm; LC Packings, Amsterdam, The
Netherlands) at 150 nl/min delivered by an Agilent 1100LC pump
(400 ml/min) and a flow splitter (Accurate, LC Packings). A mobile
Table 4. Regulation of resolution indices: lidocaine vs. isoflurane
Ymax PMN# (x10
6)T max (hours) T50 (hours) Ri (hours)
Zymosan-initiated peritonitis 17.5 12 35 23
Zymosan+lidocaine 18.5 24 45 21
Zymosan-initiated peritonitis 18.0 12 34 22
Zymosan+isoflurane 13.5 12 22 10
Resolution indices are quantitatively defined as: (i) Magnitude (Ymax, Tmax)–The time point (Tmax), following challenge or injury, when neutrophil numbers in tissues or
exudates reach maximum (Ymax); (ii) Duration (R50, T50)–The time point (T50) when the neutrophil numbers reduce to 50% of Ymax (R50); (iii) Resolution Interval (Ri)–The
time interval from the maximum neutrophil infiltration time point (Ymax) to 50% reduction point (R50)[ i.e. T502Tmax]. Lidocaine treatment enhanced the magnitude
(Ymax) and delayed the onset of resolution (Tmax). In contrast, isoflurane reduced magnitude (Ymax) and shortened resolution interval (Ri). See Figure S1 for further
details and calculations.
doi:10.1371/journal.pone.0001879.t004
Table 5. Cellular proteins regulated by isoflurane during inflammation-resolution
Spot Protein Time (h)
# identified
peptides Zymosan A Zymosan A+Lidocaine P value
Cellular protein
1 SH3 domain-binding glutamic acid-rich like
protein
12 2 104426752 1866864356 (q79%) 0.032
2 Pyruvate kinase M 12 7 13286200 21046402 (q58%) 0.048
3 Transgelin-2 12 5 22286503 11296158 (Q50%) 0.023
4 Destrin (ADF) or Cathelicidin (CRAMP) 12 22 46546190 23276765 (Q50%) 0.007
5 Cofilin-1 12 2 1004062177 43676953 (Q57%) 0.014
6 Aldolase-1 12 13 613861065 37306624 (Q40%) 0.028
7 Neutrophilic granule protein 24 3 21396410 44836318 (q110%) 0.001
8 Similar to GAPDH 24 2 1105961593 433661632 (Q61%) 0.007
The proteins were identified by mass spectrometry (see Materials and Methods).
doi:10.1371/journal.pone.0001879.t005
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0.1% formic acid), and B (80% acetonitrile/0.1% formic acid)
from 0–10 min with 0–20% B followed by 10–90 min with 20–
60% B. Peptide mass and charge was determined on a
ThermoFinnigan Advantage ion-trap mass spectrometer (San
Jose, CA) after electrospray ionization using end-coated spray
Silicatip tip (ID 75 mm, tip ID 15 mm, New Objective) held at a
spray voltage of 1.8 kV. After acquisition of the peptide parent ion
mass, zoom scans and tandem mass spectra of parent peptide ions
above a signal threshold of 2610
4 were recorded with dynamic
exclusion, using Xcalibur 1.3 data acquisition software
(ThermoFinnigan).
Protein identification. Proteins were identified by peptide
mapping of tryptic peptide tandem mass spectra using
TurboSequest (BioWorks 3.1 software, ThermoFinnigan against
indexed Swiss-Prot protein database). Protein modifications that
were taken into consideration included methionine oxidation and
alkylation of cysteine with iodoacetamide. The search results were
filtered by Xcorr vs. charge with 1.5 for singly charged ions, 2.0 for
doubly charged ions, and 2.5 for triply charged ions. A protein was
considered identified when a minimum of two tryptic peptides
were matched.
ELISA-peptide and lipid mediators
Aliquots of supernatants were used to quantitate chemokines
and cytokines using a SearchLight Mouse Chemokine Array
custom designed with Pierce Boston Technology Center. TGF-b
levels was determined with ELISA using a monoclonal anti-TGF-
b antibody (R&D Systems, Minneapolis, MN) recognizing the
active forms of TGF-b (1, 2, and 3). Eicosanoid ELISAs (LTB4,
LXA4 and PGE2) were carried out following manufacturer’s
instructions (Neogen, Lexington, KY).
Western blot
Supernatants from peritoneal lavages were collected and equal
amounts of proteins were subjected to SDS-PAGE and transferred
to a polyvinylidene fluoride (PVDF) microporous membrane by
electroblotting. Membranes were blocked in 5% non-fat milk in
TBST (0.9% NaCl and 0.05% Tween-20 in 20 mM Tris/HCl,
pH 7.4) and probed with a goat anti-mouse S100A9 polyclonal
antibody (0.2 mg/ml, R&D Systems) for 1 hour. After washing
three times with TBST, membrane were incubated with HRP-
linked anti-goat IgG (1:5,000 dilution) for 1 h and the immuno-
reactive bands were developed by incubating with chemilumines-
cence substrates and visualized by exposure to an X-ray film.
RT-PCR
Murine peritoneal cells were collected, total RNA was isolated
using TriZol reagent (GIBCO BRL, Grand Island, NY) and
reverse-transcribed followed by polymerase chain reactions (PCR)
using HotStar Master mix (Qiagen) (95uC for 15 min, then 35
cycles of 95uC for 30 sec, 55uC for 30 sec and 72uC for 60 sec)
with specific primers for mouse S100A9 (sense: 59-CCCTGA-
CACCCTGAGCA AGAAG-39 and antisense 59-TTTCCCA-
GAACAAAGGCCATTGAG-39). Relative intensities of RT-PCR
products were quantified and normalized by b-actin message levels
using the public domain NIH image program (developed at the
NIH, available on the Internet).
Statistical approaches
All results were calculated and expressed as mean6standard
error of mean (mean6SEM). Group comparisons were carried out
using one-way ANOVA or Student’s t-test where appropriate, with
P values ,0.05 taken as statistically significant (sufficient to reject
the null hypothesis).
Supporting Information
Figure S1 (A) Resolution indices: definitions and calculations. The main
events in the resolution of acute inflammation can be quantified
Table 6. Regulation of cytokines: lidocaine vs. isoflurane (4h after zymosan challenge)
Treatment Zymosan A +Lidocaine (0.08%) Zymosan A +Isoflurane (1.4 MAC)
Pro-inflammatory cytokines (pg/ml)
IL-1b 65.067.4 72.3614.8 170.0630.4 41.463.5*
IL-6 38183.766291.8 27391.466397.5 65093.3612314.0 24808.364953.4*
IL-12 11.262.7 8.662.0 9.161.6 2.761.4*
TNF-a 60.563.0 44.966.1 128.6610.6 126.868.0
KC 4489.06553.7 1808.56306.5* 6311.76961.5 2243.16890.0*
JE 5074.36523.3 3765.36319.6 8518.36802.0 5308.36535.4*
MIP-1a 137.0613.5 98.5617.6 173.5621.9 59.4621.5*
RANTES 42.864.7 45.965.9 31.765.8 11.964.7*
*Significant inhibition of zymosan-stimulated cytokine/chemokine levels
doi:10.1371/journal.pone.0001879.t006
Table 7. Regulation of cytokines: lidocaine vs. isoflurane (%
inhibition)
Treatment +Lidocaine (0.08%) +Isoflurane (1.4 MAC)
Pro-inflammatory cytokines (% inhibition by anesthetics)
IL-1b – Q 75.6% *
IL-6 – Q 61.9% *
IL-12 – Q 70.8% *
TNF-a ––
KC Q 60.7% * Q 64.5% *
JE – Q 27.7% *
MIP-1a – Q 65.8% *
RANTES – Q 62.3% *
Q
* Significant inhibition of zymosan-stimulated cytokine/chemokine levels
– No significant change
doi:10.1371/journal.pone.0001879.t007
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Magnitude (Ymax,T max)–The time point (Tmax), following
challenge or injury, when neutrophil numbers in tissues or
exudates reach maximum (Ymax); (ii) Duration (R50,T 50)–The
time point (T50) when the neutrophil numbers reduce to 50% of
Ymax (R50); (iii) Resolution Interval (Ri)–The time interval from
the maximum neutrophil infiltration time point (Ymax) to 50%
reduction point (R50)[ i.e.T 50-Tmax]. For calculating specific
resolution indices and further details, see ref. 8. (B) Lidocaine
treatment alone. Mice were injected with lidocaine (0.08%) or saline
and peritoneal lavages were collected 4 and 24 h after injection.
Total leukocytes were enumerated by light microscopy. Results are
expressed as the mean of two separate experiments. (C) Resolution
Indices calculated with lidocaine. Lidocaine treatment enhances the
magnitude (Ymax) and delays the onset (Tmax) of resolution.
Found at: doi:10.1371/journal.pone.0001879.s001 (2.38 MB TIF)
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